PD738 - MULTI-OMICS PAN-CANCER ANALYSIS OF TIPE2 IDENTIFIES IMMUNE MICROENVIRONMENT ASSOCIATIONS AND IMMUNOTHERAPEUTIC RELEVANCE

PD738

MULTI-OMICS PAN-CANCER ANALYSIS OF TIPE2 IDENTIFIES IMMUNE MICROENVIRONMENT ASSOCIATIONS AND IMMUNOTHERAPEUTIC RELEVANCE

Z. Li^1,*, S. Cao¹, Y. Zhou¹

¹Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, Qingdao, China

Rationale: TIPE2 (TNFAIP8L2) is a regulator of immune homeostasis, but its pan-cancer relevance to the tumor immune microenvironment remains unclear. We evaluated the expression, immune associations, genomic and epigenetic alterations, and prognostic value of TIPE2 across human cancers. 

Methods: Multi-omics analyses were performed using TCGA, GTEx, HPA, UCSC Xena, cBioPortal, UALCAN, TIMER, xCell, and gene set enrichment analysis across 33 cancer types. Associations with immune cell infiltration, immune checkpoint genes, methylation, gene alterations, and survival were assessed. 

Results: TIPE2 was highly expressed in lymphoid and immune tissues and showed expression in 31 tumor types comparable to or higher than normal tissues. It was significantly upregulated in GBM, KIRC, KIRP, LAML, LGG, OV, PAAD, SKCM, and TGCT. TIPE2 expression correlated with immune infiltration across most cancers and showed broad positive associations with immune checkpoint genes. TIPE2 alterations were detected in 4.0% (457/10967) of pan-cancer cases, predominantly amplifications, and hypomethylation was observed in 14 tumor types. Gene set enrichment analysis linked high TIPE2 expression to immune-related pathways. Prognostic associations were tumor-context dependent, with favorable signals in ACC, CHOL, BRCA, CESC, DLBC, SARC, and SKCM, but unfavorable associations in PRAD, LGG, and UVM. 

Conclusion: TIPE2 is an immune-enriched pan-cancer biomarker associated with the tumor immune microenvironment, checkpoint-related signaling, and tumor-specific prognosis. It may help refine immunotherapy-oriented stratification, but mechanistic and clinical validation remains necessary. 

Disclosure of Interest: None declared